ORGO — Organogenesis Holdings Inc.
Is ORGO overbought or oversold? Here is the current MarketMoodz read.
Organogenesis Holdings Inc. (ORGO) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $0.80. The rating moved from Neutral to Oversold on November 14, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$0.80
- Last changeMoved from Neutral to Oversold on November 14, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
See all oversold Healthcare stocks →
AI analysis
Organogenesis Holdings Inc. (ORGO) is a small-cap specialist in wound-care and regenerative products with limited public financial transparency. Sector readthroughs that favor specialty distribution and outpatient care are constructive, but the company’s near-term outlook depends heavily on commercialization execution, payer coverage, and access to financing. Given thin liquidity, high operational risk, and scarce social/EDGAR signals, the stock is likely to remain volatile until clearer financial reports or tangible commercial milestones emerge.
Key factors
- Niche market position in wound care and regenerative-tissue products with specialized clinical use cases
- Sector themes favor outpatient, specialty-distribution channels which could support product flow over time
- Limited recent public financial disclosure and no EDGAR comparison available increases information asymmetry
- Macro tone is cautious optimism with flow to healthcare defensives, which may provide intermittent support
- Product commercialization and reimbursement dynamics are the primary drivers of near-term revenue
- Potential for operational or balance-sheet events (financings, restructurings) given small-cap status
Risks
- Thin liquidity and small market cap leading to high price volatility
- Limited available filings and lack of up-to-date EDGAR analysis reduce visibility into financial health
- Reimbursement pressure and changing payer dynamics (including Medicare Advantage program shifts)
- Competition from larger medtech/biotech players and alternative wound-care solutions
- Possible dilution from future financings or convertible instruments
- Regulatory setbacks or product performance issues that could derail commercialization
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for ORGO — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.